Evogene (NASDAQ:EVGN) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

Shares of Evogene Ltd. (NASDAQ:EVGN) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.40 and traded as low as $1.46. Evogene shares last traded at $1.48, with a volume of 42,424 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Evogene in a research report on Friday. They set a “sell” rating on the stock.

Evogene Trading Up 4.5 %

The company has a market capitalization of $8.31 million, a price-to-earnings ratio of -0.35 and a beta of 1.29. The firm has a 50-day moving average price of $1.57 and a 200-day moving average price of $2.37.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.40% of Evogene as of its most recent filing with the Securities and Exchange Commission. 10.40% of the stock is currently owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.